Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide
Bryce C Simes, Gordon G MacGregor Alabama College of Osteopathic Medicine, Dothan, AL, USACorrespondence: Bryce C SimesAlabama College of Osteopathic Medicine, 445 Health Sciences Blvd., Dothan, AL 36303, USATel +1 205 904-504-8897Fax +1 205 334-699-2268Email simesbc@acom.eduAbstract: This comprehen...
Saved in:
Main Authors: | Simes BC, MacGregor GG |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2019
|
Subjects: | |
Online Access: | https://doaj.org/article/a9a6921fe05e45a0b9d4d1b0f8d9704f |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
by: Santos Cavaiola T, et al.
Published: (2018) -
DECLARE-TIMI 58 trial in the context of EMPA-REG OUTCOME and CANVAS
by: Marina V. Shestakova
Published: (2019) -
SGLT2 inhibitors and the changing landscape for treatment of diabetes
by: Liu S, et al.
Published: (2019) -
Cost-Effectiveness of Adding SGLT2 Inhibitors to Standard Treatment for Heart Failure With Reduced Ejection Fraction Patients in China
by: Yaohui Jiang, et al.
Published: (2021) -
Canagliflozin review – safety and efficacy profile in patients with T2DM
by: Jakher H, et al.
Published: (2019)